Pruvanserin (INNTooltip International Nonproprietary Name; USANTooltip United States Adopted Name; developmental code names EMD-281,014, LY-2422347) is a selective serotonin 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline.
Pharmacology
Pharmacodynamics Pruvanserin acts as a selective serotonin 5-HT2A receptor antagonist. In addition to its sleep-improving properties, pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies.
Pharmacodynamics The time to peak levels of pruvanserin is 2 to 3 hours, with a range of 2 to 6 hours. The mean elimination half-life of pruvanserin is 8.6 to 9.5 hours, with a range of 3.9 to 12.4 hours. However, its brain serotonin 5-HT2A receptor occupancy lasts much longer, with a half-life of approximately 24 hours.
See also Serotonin 5-HT2A receptor antagonist List of investigational insomnia drugs Eplivanserin Pimavanserin Glemanserin Roluperidone Volinanserin Ziprasidone Lenperone Lidanserin
References


